• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • Samples
    • MRI Images
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

The Clinical Candidate Selection Process

We set up a Clinical Candidate Selection Committee (CCSC), which was a vital part of the EPAD application process. It was not only an evaluation committee but was also the first point of contact with EPAD for intervention owners, and a facilitator of the candidate nomination process.  The CCSC:

  • Maintained an open and transparent selection process.
  • Relied on regulatory authorities to ensure that interventions have met the regulatory requirements to advance to Phase II.
  • Supported de-risking the EPAD project by assuring the scientific rationale, safety, and appropriateness of using EPAD to establish PoC for a given intervention.

What were the selection criteria?

All interventions were evaluated against the following nine criteria and rated accordingly.

  1. Scientific rationale/target validation
  2. Pharmacokinetics (PK)
  3. Pharmacology requirements
  4. Safety
  5. Plans for full development/regulatory issues
  6. Develop-ability/CMC quality guidelines
  7. Biomarkers: assays available for use in the PoC

The PoC master protocol outlines our study design and requirements for all interventions.

EPAD Application Process

The application and access process contained a number of steps but was designed to be as simple as possible.

The EPAD PoC platform was open for expressions of interest from intervention owners including pharmaceutical and biotechnology organisations, academic researchers, and funders.

Before the application process could begin, all parties signed a non-disclosure agreement. The Clinical Candidate Selection Committee (or CCSC) then conducted a scientific review to ensure that the intervention was suitable for EPAD. If approved, an examination of statistical and operational requirements followed.

If all parties agreed, this stage was concluded with the signing of a letter of intent signifying the intervention owner’s commitment to the EPAD PoC.

EPAD flow

  1. Approach: The intervention owner contacted the CCSC via email, or downloads, completed and sent an Expression of Interest to the EPAD PoC team.
  2. Assess: The CCSC reviewed and identified potentially suitable interventions and had preliminary discussions with the intervention owner. The CCSC provided the template Non-Disclosure Agreement, Nomination Form, and instructions on how to apply, to the intervention owner.
  3. Submit: All parties signed the Non-Disclosure Agreement and the intervention owner submitted the Nomination Form.
  4. Review: The CCSC conducted a preliminary review of Nomination Form to determine whether additional experts were needed for the review and the formal CCSC review meeting date was set. If additional experts were required, the intervention owner consented to their involvement.
  5. Decide: The CCSC review meeting with the intervention owner was conducted and a formal decision was made. Subsequently an operational and statistical review meeting with the PoC team and intervention owner was conducted to determine if their requirements were possible within the EPAD PoC platform.
  6. Establish: If accepted, the intervention owner signed the Letter of Intent, which triggered the constitution of the Appendix Writing Group. This group was led by the intervention owner and included EPAD representatives. The Letter of Intent included the fees payable by the intervention owner for the scientific, statistical and operational resources required to complete an appendix synopsis.
  7. Finalise: The Appendix Writing Group worked on their appendix in collaboration with the EPAD team to finalise the study design elements.
  8. Review: The legal agreements and budget were reviewed per EPAD requirements and approvals received.
  9. Commence: The Appendix Writing Group reconvened as the Appendix Steering Committee to initiate study start-up activities.  Once approvals were received by the sponsor, recruitment from the Longitudinal Cohort Study begins and the trial commenced.
Share this page
FacebookTwitterLinkedInGoogle+
Latest News
  • The final EPAD dataset is now available to the entire research community
    2020-11-30
  • ALZFORUM
    Alzforum conference blog mentions EPAD
    2020-11-30
  • EPAD v1500 dataset
    New webpage dedicated to EPAD data and samples on the EPAD website
    2020-11-18
  • ADDI launches new Workbench to foster greater global research innovation and accelerate breakthroughs in Alzheimer’s disease and related dementias
    2020-11-17
  • New paper investigating the prediction of Alzheimer’s disease biomarker status
    2020-11-12
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

We would like to thank all our followers! A massive thanks also goes to our research participants & members for all their support! Looking back on the years of the @IMI_EPAD project, here's key pictures took at major events. Have a safe & Happy New Year! youtu.be/FeYsOBOhCeo

reply retweet favorite
8:55 am · 2021-01-18
Twitter
EPAD
EPAD
@IMI_EPAD

The videos from #30AEC are online! Check out the @IMI_EPAD presentations on #data sharing by @rodrigobarnes (@aridhia) & Colin Veal (@uniofleicester). Thanks @IMI2_NEURONET and @AlzheimerEurope for giving us the opportunity to present our work. imi-neuronet.org/2020-virtual… twitter.com/IMI2_NEURONET/…

reply retweet favorite
8:43 am · 2021-01-15
Twitter
EPAD
EPAD
@IMI_EPAD

Authors investigated #data from nine studies, including @IMI_EPAD, comprising a total of 60,004 assessed participants. If you want to explore the #Alzheimer's disease data landscape, visit adata.scai.fraunhofer.de @BirkenbihlC @ApitiusHofmann @ddomingof @Simon_Lovestone @TVB_cloud

reply retweet favorite
7:56 am · 2021-01-11
Twitter
EPAD
EPAD
@IMI_EPAD

Numerous studies have collected #Alzheimer's disease cohort #data sets. @BirkenbihlC and colleagues have evaluated the Alzheimer's disease data landscape from a patient‐level data‐centric perspective. @IMI_EPAD @IMI_EMIF @NACCALZ alz-journals.onlinelibrary.wi…

reply retweet favorite
7:48 am · 2021-01-11
Twitter
EPAD
EPAD
@IMI_EPAD

The final @IMI_EPAD dataset is now available to the entire research community | News | @CORDIS_EU | European Commission europa.eu/!dj89jY

reply retweet favorite
12:55 pm · 2021-01-08
Copyright © 2015-19 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.